Drug price reduction policies have been introduced one after another, and the magic spell of drug enterprises' single product needs to be broken!

[pharmaceutical network industry trends] in recent years, with the continuous promotion of 4 + 7 volume purchase, consistency evaluation, and other drug price reduction policies, drug price reduction has become an irreversible trend Under the influence of policies and the fierce competition of products, some enterprises that rely on core products to maintain their contribution income also have fluctuations in their performance, and the magic spell of single product remains to be broken At present, the situation of "unique products" in some pharmaceutical enterprises is still obvious For example, since Beida pharmaceutical was listed on the growth enterprise market of Shenzhen Stock Exchange in 2016, ektini has been the core product of the company In 2016, 2017 and 2018, the revenue contributed by ektini was 1.035 billion yuan, 1.026 billion yuan and 1.208 billion yuan respectively, accounting for 99.98%, 99.96% and 98.69% of the company's operating revenue in that year Under the influence of the drug price reduction policy, exetane also made a big price reduction, which directly affected the performance of Beida pharmaceutical industry In 2016, after drug price negotiation, exetane reduced 54%; after being included in the national medical insurance catalog in February 2017, it was still reducing its price; in July 2018, Beida pharmaceutical reduced the price of Internet in each province of exetane from 1399 yuan / box to 1345.05 yuan / box, that is, 64.05 yuan per tablet The adjusted price of ektini is valid until December 31, 2019 For another example, Shuanglu pharmaceutical's single product complex coenzyme accounts for half of the company's revenue, but it has also been affected by policies since this year The list of key monitoring drugs released in July this year includes 20 kinds of auxiliary drugs such as compound coenzyme, which means that compound coenzyme will be strictly monitored, including two specifications of compound coenzyme products of Shuanglu pharmaceutical industry - beconone and xinbeike Recently, the state health insurance bureau has stipulated that the provincial supplement to the list of Medicare drugs should be digested and completed within three years according to the principle of 442, respectively according to 40%, 40% and 20% of the number of supplements in each province, and monitoring auxiliary drugs should be removed from the list first The compound coenzyme of Shuanglu pharmaceutical industry is also included, which means that the compound coenzyme will gradually withdraw from local medical insurance in the next three years, and its impact on Shuanglu pharmaceutical industry can be imagined The industry believes that although many pharmaceutical companies have created myths by relying on a single variety, the most beautiful myth will fall into the altar one day In the context of the trend of drug price reduction and more stringent drug regulation, the magic spell of single product of pharmaceutical enterprises needs to be broken The magic spell of single product is to be broken Under the background of DRGs, which is organized by the state to purchase drugs with volume and gradually enlarged, pharmaceutical enterprises must break the magic spell of single product Although the core varieties can bring many profits and market shares for enterprises, the acquisition and creation of new products are the driving force for the growth of enterprises, and the continuous innovation of products can promote the sustainable development of enterprises At the same time, pharmaceutical companies also need to escape from the vicious competition of "sales with gold", improve the quality of drugs and promote drug research and development Volume purchase helps to break this vicious competition and eliminate the situation of high drug price Pharmaceutical companies only focus on product research and development, because the low cost and high quality of products is the hard truth to survive in the pharmaceutical industry in the future At present, many pharmaceutical enterprises have begun to seek new development opportunities, break the traditional single product imprisonment, from a single product to full bloom, with the successive efforts of multiple follow-up products, the future promotion space is still very large In addition, pharmaceutical enterprises integrate their resource advantages through acquisition, merger and acquisition, so as to help enterprises achieve balanced growth and all-round development.